SUZHOU, China and ROCKVILLE,
Md., April 24, 2024 /PRNewswire/ -- Ascentage
Pharma (6855.HK), a global biopharmaceutical company engaged in
developing novel therapies for cancer, chronic hepatitis B (CHB),
and age-related diseases, announced today that results from four
clinical studies of the company's three key drug candidates have
been selected for presentations, including an Oral Report, at the
2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
The three drugs are olverembatinib (HQP1351), the first and only
China-approved third-generation
BCR-ABL inhibitor; lisaftoclax (APG-2575), a Bcl-2-selective
inhibitor; and APG-2449, a FAK/ALK/ROS1 inhibitor.
The ASCO Annual Meeting showcases the most cutting-edge research
in clinical oncology and state-of-the-art advanced cancer therapies
and is the world's most influential and prominent scientific
gathering of the clinical oncology community. This year's ASCO
Annual Meeting will take place both online and in-person at the
McCormick Place, Chicago, IL,
the United States, on May 31–June
4, 2024 (local time).
"Entering the seventh consecutive year for our studies to be
selected for presentations at the ASCO Annual Meeting, we are
honored to have the opportunity to once again showcase our
capabilities in global innovation and clinical development at this
top international scientific meeting," said Dr. Yifan Zhai, Chief Medical Officer of Ascentage
Pharma. "Our presentations this year include an Oral
Report featuring updated data of olverembatinib in patients with
succinate dehydrogenase (SDH)-deficient gastrointestinal stromal
tumor (GIST), an indication that currently has no effective
treatment. Furthermore, we will release detailed data of
lisaftoclax in patients with acute myeloid leukemia (AML) and in
patients with Waldenstrom macroglobulinemia (WM), as well as those
of APG-2449 in patients with non-small cell lung cancer (NSCLC). We
look forward to sharing the detailed results from those studies
with our colleagues at the meeting. Moving forward, we will remain
dedicated to those global clinical development programs of key
candidates to hopefully bring more treatment options to patients in
need."
These four clinical studies to be presented at this year's
ASCO Annual Meeting are as follows:
Olverembatinib
Updated efficacy results of
olverembatinib (HQP1351) in patients with tyrosine kinase inhibitor
(TKI)-resistant succinate dehydrogenase (SDH)-deficient
gastrointestinal stromal tumor (GIST) and
paraganglioma
Abstract#: 11502
Format: Oral Report
Session Title: Sarcoma
Date and Time: June 3, 2024, Monday,
3:00 PM – 6:00
PM (Central Time)
First Author: Haibo Qiu, MD, PhD, Sun
Yat-sen University Cancer Center, Guangzhou, Guangdong, China.
APG-2575 (Lisaftoclax)
Safety and efficacy of
lisaftoclax, a novel BCL-2 inhibitor, in combination with
azacitidine in patients with treatment-naïve or relapsed or
refractory acute myeloid leukemia
Abstract#: 6541
Format: Poster Presentation
Session Title: Hematologic Malignancies—Leukemia, Myelodysplastic
Syndromes, and Allotransplant
Date and Time: June 3, 2024, Monday,
9:00 AM – 12:00 PM (Central Time)
First Author: Huafeng Wang, MD, PhD,
The First Affiliated Hospital, Zhejiang University School of
Medicine, Hangzhou, Zhejiang, China.
Updated efficacy and safety results of BCL-2 inhibitor
lisaftoclax (APG-2575) alone or combined with ibrutinib or
rituximab in patients (pts) with Waldenström
macroglobulinemia (WM)
Abstract#: 7078
Format: Poster Presentation
Session Title: Hematologic
Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Date and Time: June 3, 2024, Monday,
9:00 AM– 12:00 PM (Central Time)
First Author: Masa Lasica, MBBS, FRACP, FRCPA, St Vincent's
Hospital, Melbourne, Victoria, Australia.
APG-2449
Updated study results of novel
FAK/ALK/ROS1 inhibitor APG-2449 in patients (pts) with
non-small-cell lung cancer (NSCLC) resistant to second-generation
ALK inhibitors.
Abstract#: 3124
Format: Poster Presentation
Session Title: Developmental Therapeutics—Molecularly Targeted
Agents and Tumor Biology
Date and Time: June 1, 2024,
Saturday, 9:00 AM – 12:00 PM (Central Time)
First Author: Yuxiang Ma, MD, PhD, Sun
Yat-sen University Cancer Center, Guangzhou, Guangdong, China.
About Ascentage Pharma
Ascentage Pharma (6855.HK) is a globally focused
biopharmaceutical company engaged in developing novel therapies for
cancers, chronic hepatitis B, and age-related diseases. On
October 28, 2019, Ascentage Pharma
was listed on the Main Board of the Stock Exchange of Hong Kong
Limited with the stock code 6855.HK.
Ascentage Pharma focuses on developing therapeutics that inhibit
protein-protein interactions to restore apoptosis, or programmed
cell death. The company has built a pipeline of 9 clinical drug
candidates, including novel, highly potent Bcl-2, and dual
Bcl-2/Bcl-xL inhibitors, as well as candidates aimed at IAP and
MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors
(TKIs). Ascentage Pharma is also the only company in the world with
active clinical programs targeting all three known classes of key
apoptosis regulators. The company is conducting more than 40 Phase
I/II clinical trials, including 5 global registrational phase III
studies, in the US, Australia,
Europe, and China. Ascentage Pharma has been designated
for multiple Major National R&D Projects, including five Major
New Drug Projects, one New Drug Incubator status, four Innovative
Drug Programs, and one Major Project for the Prevention and
Treatment of Infectious Diseases.
Olverembatinib, the company's core drug candidate developed for
the treatment of drug-resistant chronic myeloid leukemia (CML) and
the company's first approved product, has been granted Priority
Review Designations and Breakthrough Therapy Designations by the
Center for Drug Evaluation (CDE) of China National Medical Products
Administration (NMPA). To date, the drug had been included into the
China 2022 National Reimbursement
Drug List (NRDL). Furthermore, olverembatinib has been granted an
Orphan Drug Designation (ODD) and a Fast Track Designation (FTD) by
the US FDA, and an Orphan Designation by the EMA of the EU. To
date, Ascentage Pharma has obtained a total of 16 ODDs from the US
FDA and 1 Orphan Designation from the EMA of the EU for 4 of the
company's investigational drug candidates.
Leveraging its robust R&D capabilities, Ascentage Pharma has
built a portfolio of global intellectual property rights and
entered into global partnerships with numerous renowned
biotechnology and pharmaceutical companies and research institutes
such as UNITY Biotechnology, MD Anderson Cancer Center, Mayo
Clinic, Dana-Farber Cancer Institute, MSD, and AstraZeneca. The
company has built a talented team with global experience in the
discovery and development of innovative drugs and is setting up its
world-class commercial manufacturing and Sales & Marketing
teams. One pivotal aim of Ascentage Pharma is to continuously
strengthen its R&D capabilities and accelerate its clinical
development programs, in order to fulfil its mission of addressing
unmet clinical needs in China and
around the world for the benefit of more patients.
Forward-Looking Statements
The forward-looking statements made in this article relate only
to the events or information as of the date on which the statements
are made in this article. Except as required by law, Ascentage
Pharma undertakes no obligation to update or revise publicly any
forward-looking statements, whether as a result of new information,
future events, or otherwise, after the date on which the statements
are made or to reflect the occurrence of unanticipated events. You
should read this article completely and with the understanding that
our actual future results or performance may be materially
different from what we expect. In this article, statements of, or
references to, our intentions or those of any of our Directors or
our Company are made as of the date of this article. Any of these
intentions may alter in light of future development.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/asco-2024--ascentage-pharma-to-present-four-studies-including-an-oral-report-featuring-the-latest-data-of-olverembatinib-in-sdh-deficient-gist-302126836.html
SOURCE Ascentage Pharma